The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review
Antibodies · 13.07.2026 · 15 (4) · 60
DOI: 10.3390/antib15040060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 13.07.2026. Verfasst von Christian D'Elia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, 50134 Florence, Italy. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most severe extra-articular manifestations of rheumatoid arthritis (RA), requiring reliable biomarkers for early detection. This scoping review synthesized current evidence regarding the diagnostic performance and clinical associations of anti-mutated citrullinated vimentin (anti-MCV) antibodies in patients with RA-ILD. A comprehensive literature search was conducted across PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library. Following systematic screening, two observational studies met the predefined inclusion criteria. Both included studies reported significantly higher anti-MCV positivity rates and/or serum levels in patients with RA-ILD compared with RA patients without pulmonary involvement. Specifically, one study identified an independent association between anti-MCV positivity and RA-ILD, while the other demonstrated significant correlations between anti-MCV titers and pulmonary function impairment, as well as disease activity markers. However, substantial heterogeneity was observed across the studies regarding assay platforms, positivity thresholds, and diagnostic cut-offs, which limits the direct comparability of results. While anti-MCV antibodies represent promising candidate biomarkers for RA-ILD, current evidence remains limited and is insufficient to establish definitive diagnostic, prognostic, or pathogenic significance. Consequently, larger, prospective, and multi-center studies utilizing standardized anti-MCV assay protocols are necessary to rigorously evaluate the clinical utility of these antibodies in the management of RA-ILD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, 50134 Florence, Italy.
- Sebia, Carl-Zeiss-Straße 49-51, 55129 Mainz, Germany.
- Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, 50143 Florence, Italy.
- Rheumatology Unit, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, 50143 Florence, Italy.
ORCID-Profile: Christian D'Elia, Serena Guiducci, Maria Infantino, Maurizio Benucci
Zitieren
APA
D'Elia, C., Santagata, G., Guiducci, S., Bang, H., Manfredi, M., Infantino, M., & Benucci, M. (2026). The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review. Antibodies, 15(4), 60. https://doi.org/10.3390/antib15040060
Vancouver
D'Elia C, Santagata G, Guiducci S, Bang H, Manfredi M, Infantino M, et al. The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review. Antibodies. 2026;15(4):60. doi:10.3390/antib15040060
BibTeX
@article{DElia2026,
author = {D'Elia, Christian and Santagata, Giada and Guiducci, Serena and Bang, Holger and Manfredi, Mariangela and Infantino, Maria and Benucci, Maurizio},
title = {The Diagnostic and Clinical Significance of Anti-Mutated Citrullinated Vimentin Antibodies in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Scoping Review},
journal = {Antibodies},
year = {2026},
volume = {15},
number = {4},
pages = {60},
doi = {10.3390/antib15040060}
}
EUVIMED